Neurologian yksikkö
Department of Neurology

Julkaisut 2001
Publications 2001

Lisätietoja julkaisusta saa klikkaamalla sen numeroa.
For full details, please click the number in front of the publication.


1 Alafuzoff I. Neuropatologinen tutkimus.
2 Alamowitch S et al. Risk, causes, and prevention of ischaemic stroke in elderly patients with symptomatic internal-carotid-artery stenosis.
3 Antikainen R et al. Mood improvement reduces memory complaints in depressed patients.
4 Benavente O et al. Prognosis after transient monocular blindness associated with carotid-artery stenosis.
5 Bezvenyuk Z. Multiple Pathways of DNA Disintegration During Neuronal Apoptosis.
6 Björklund M et al. Spatial working memory improvement by an alpha2-adrenoceptor agonist dexmedetomidine is not mediated through alpha2C- adrenoceptor.
7 Butovas S et al. Differential effect of the alfa2-adrenoceptor antagonist, atipamezole, in limb-placing task and skilled forepaw use following experimental stroke.
8 Clarke NA et al. Tacrine may alter APP-like protein levels in the lumbar CSF of Alzheimer patients.
9 Du AT et al. Magnetic resonance imaging of the entorhinal cortex and hippocampus in mild cognitive impairment and Alzheimer´s disease.
10 Eloniemi-Sulkava U et al. Effects of supporting community-living demented patients and their caregivers: A randomized trial.
11 Elovaara I et al. Immunoglobuliinin käyttö neurologisten tautien hoidossa.
12 Erkinjuntti T, Pirttilä T. Vaskulaariset dementiat.
13 Erkinjuntti T et al., toim. Muistihäiriöt ja dementia.
14 Erkinjuntti T et al. Muistihäiriöt ja dementia.
15 Everson SA et al. Stress-induced blood pressure reactivity and incident stroke in middle-aged men.
16 Finnilä S et al. Increased risk of sensorineural hearing loss and migraine in patients with a rare mitochondrial DNA variant 4336A>G in tRNA.
17 Grieve R et al. A comparison of the costs and survival of hospital-admitted stroke patients across Europe.
18 Heinonen S et al. Maternal susceptibility locus for obstetric cholestasis maps to chromosone region 2p13 in finnish patients.
19 Heinonen S et al. Apolipoprotein E alleles in women with polycystic ovary syndrome.
20 Heiskanen JT et al. Insertion-deletion polymorphism in the gene for angiotensin-converting enzyme is associated with obstetric cholestasis but not with preeclampsia.
21 Helenius M et al. Characterization of aging-associated up-regulation of constitutive nuclear factor-kappaB binding activity.
22 Hiltunen M et al. Genome-wide linkage disequilibrium mapping of late-onset Alzheimr´s disease in Finland.
23 Hiltunen M, Soininen H. Genes, proteins and brain disease.
24 Hokkanen L et al. Kognitiiviset häiriöt ja niiden tutkiminen.
25 Hänninen T, Pirttilä T. Varhaiset neuropsykologiset muutokset dementiassa. Kokemuksia Cerad-tehtäväsarjan käytöstä.
26 Ihalainen JA et al. alpha2c-Adrenoceptors modulate the effect of methylphenidate on response rateand discrimination accuracy in an operant test.
27 Ikonen M. Apoptosis-associated Changes in Neuronal Gene Expression. With Special Emphasis on the Insulin-like Growth Factor System.
28 Ikonen S. The Role of the Septohippocampal Cholinergic System in Cognitive Functions.
29 Ikonen S, Tanila H. Effects of metrifonate on the hippocampal theta rhythm of freely moving intact and MS-lesioned mice.
30 Jakovljevic D et al. Socioeconomic status and ischemic stroke: the FINMONICA stroke register.
31 Jakovljevic D et al. Socioeconomic differences in the incidence, mortality and prognosis of intracerebral hemorrhage in Finnish adult population.
32 Jakovljevic D et al. Socioeconomic inequalities in the incidence, mortality and prognosis of subarachnoid hemorrhage: the FINMONICA stroke register.
33 Jolkkonen E et al. Projections from the amygdalo-piriform transition area to the amygdaloid coplex: A PHA-L study in rat.
34 Jolkkonen J et al., ed. 11th Nordic Meeting on Cerebrovascular Diseases and 2nd Biennial Symposium on Ischaemic Stroke.
35 Jutila L et al. Neurobiology of epileptogenesis in the temporal lobe.
36 Jutila L et al. MR volumetry of the entorhinal, perirhinal, and temporopolar cortices in drug-refractory temporal lobe epilepsy.
37 Karonen J. Diffusion and Perfusion Magnetic Resonance Imaging in Human Acute Ischemic Stroke.
38 Karonen JO et al. Diffusion and perfusion MR imaging in acute ischemic stroke: a comparison to SPECT.
39 Kaste M et al. Aivoverenkiertohäiriöt.
40 Kerokoski P et al. Beta-amyloid (1-42) affects MTT reduction in astrocytes: implications for vesicular trafficking and cell functionality.
41 Kerokoski P et al. The levels of cdk5 and p35 proteins and tau phosphorylation are reduced during neuronal apoptosis.
42 Kivipelto M et al. Midlife vascular risk factors and late-life mild cognitive impairment. A population-based study.
43 Kivipelto M et al. Midlife vascular risk factors and Alzheimer´s disease in later life: longitudinal, population based study.
44 Kraszpulski M et al. The load and distribution of beta-amyloid in brain tissue of patients with Alzheimer´s disease.
45 Kuhmonen J et al. Effects of dexmedetomidine after transient and permanent occlusion of the middle cerebral artery in the rat.
46 Kurl S et al. Systolic blood pressure response to exercise stress test and risk of stroke.
47 Kuusisto E et al. Ubiquitin-binding protein p62 is present in neuronal and glial inclusions in human tauopathies and synucleinopathies.
48 Kuusisto E et al. Ubiquitin-binding protein p62 expression is induced during apoptosis and proteasomal inhibition in neuronal cells.
49 Kälviäinen R. Epilepsia ja ikääntyminen. Pääkirjoitus.
50 Kälviäinen R. Monotherapy trial design: conversion versus de novo.
51 Kälviäinen R. Long-term safety of tiagabine.
52 Kälviäinen R. Ikääntyneiden epilepsia yleistyy.
53 Kälviäinen R. Epilepsialääkkeet säilytettävä edelleen erityiskorvattavina.
54 Kälviäinen R. Terveiset Buenos Airesista.
55 Kälviäinen R. Kiitos luottamuksestanne.
56 Kälviäinen R, Keränen T. Epilepsia.
57 Kälviäinen R, Nousiainen I. Visual field defects with vigabatrin. Epidemiology and therapeutic implications .
58 Kälviäinen R, Äikiä M. Kognitiiviset häiriöt neurologisissa sairauksissa. Epilepsia.
59 Laakso M. Linkkejä muistihäiriö- ja dementiasivuille.
60 Laakso MP et al. A morphometric MRI study of the hippocampus in first-episode, neuroleptic-naive schizophrenia.
61 Laakso MP et al. Psychopathy and the posterior hippocampus.
62 Laitinen JT et al. [35S]GTPgammaS autoradiography reveals a wide distribution of Gi/o-linked ADP receptors in the nervous system: close similarities with theplatelet P2Y ADP receptor.
63 Laitinen KSM et al. Brain prolyl oligopeptidase activity is associated with neuronal damage rather than beta-amyloid accumulation.
64 Lamusuo S et al. [18F] FDG-PET reveals temporal hypometabolism in patients with temporal lobe epilepsy even when quantitative MRI and histopathological analysis show only mild hippocampal damage.
65 Luostarinen L et al. Association between coeliac disease, epilepsy and brain atrophy.
66 Luostarinen LK et al. Coeliac disease in patients with cerebellar ataxia of unknown origin.
67 Mehta PD et al. Amyloid beeta protein 1-40 and 1-42 levels in matched cerebrospinal fluid and plasma from patients with Alzheimer disease.
68 Mikkonen M et al. Hippocampal plasticity in Alzheimer´s disease.
69 Nousiainen I et al. No reversion in vigabatrin-associated visual field defects.
70 Ojala M et al. Epilepsia ja ajokyvyn arviointi - suomalainen menettelyohje.
71 Ojala M, Kälviäinen R. Insurability of patients with epilepsy: perspectives of physicians and insurance companies.
72 Parkkinen L et al. alpha-Synuclein pathology is highly dependent on the case selection.
73 Pirskanen M et al. An association between a subset of Finnish late-onset Alzheimer´s disease and alpha2-macroglobulin.
74 Pirttilä T, ed. The Second Kuopio Alzheimer Symposium. Kuopio Music Centre, Kuopio, Finland March 13-15, 2001. Program and abstracts.
75 Pirttilä T. Kolinerginen lääkehoito Alzheimerin taudissa - osa hyvää hoitoa.
76 Pirttilä T. Kliininen tutkimus.
77 Pirttilä T. Laboratoriotutkimukset.
78 Pirttilä T. Biologiset merkkiaineet.
79 Pirttilä T. Targeted drug treatment for Alzheimer´s disease.
80 Pirttilä T, Erkinjuntti T. Alzheimerin taudin kliininen kuva ja diagnoosi.
81 Pirttilä T, Oksi J. Tarvitaanko selkäydinnestetutkimuksia 2000-luvulla?
82 Puurunen K. The Effects of Pharmacotherapy and Training on Functional Recovery after Global and Focal Cerebral Ischemia in Rats.
83 Puurunen K et al. An alfa2-adrenergic antagonist, atipamezole, facilitates behavioral recovery after focal cerebral ischemia in rats.
84 Puurunen K et al. Selegiline combined with enriched-environment housing attenuates spatial learning deficits following focal cerebral ischemia in rats.
85 Rahkonen T et al. Systematic intervention for supporting community care of elderly people after a delirium episode.
86 Rissanen TH et al. Low serum lycopene concentration is associated with an excess incidence of acute coronary events and stroke: the Kuopio Ischaemic Heart Disease Risk Factor Study.
87 Roschier M et al. Insulin-like growth factor binding protein 5 and type- 1 insulin-like growth factor receptor are differentially regulated during apoptosis in cerebellar granule cells.
88 Ruutiainen J, Sivenius J. Etenevät neurologiset sairaudet.
89 Salmenperä T. Damage in the Hippocampus, Amygdala, Entorhinal and Perirhinal cortex of Adults With Partial Epilepsy.
90 Salmenperä T et al. Hippocampal and amygdaloid damage in partial epilepsy A cross-sectional MRI study of 241 patients.
91 Savolainen S et al. Auditory event-related potentials differentiate patients with normal pressure hydocephalus and patients with concomitant Alzheimer´s disease verified by brain biopsy.
92 Schmidt D et al. Recommendations on the clinical use of oxcarbazepine in the treatment of epilepsy: a consensus view.
93 Schuff N et al. MRI of entorhinal cortex and hippocampus in Alzheimer´s disease, subcortical ischemic vascular dementia and mixed dementia.
94 Sivenius J. Ikääntyneen aivohalvauspotilaan hoidon ja kuntoutuksen periaatteita.
95 Sivenius J. Aivohalvauspotilaan kuntoutuksen vaikuttavuus ja käytännön periaatteet.
96 Sivenius J et al. Selegiline treatment facilitates recovery after stroke.
97 Sivenius J, Tarkka IM. Aivovauriot.
98 Soininen H. Muistihäiriöiden ja dementian ennaltaehkäisy.
99 Soininen H, Hänninen T. Muistihäiriöiden oirediagnostiikka.
100 Soininen H, Partanen J. Kliinis-neurofysiologiset tutkimukset.
101 Sorri I. Effects of Antiepileptic Drugs on Visual Function, with Special Reference to Vigabatrin.
102 Tanila H. Noradrenergic regulation of hippocampal place cells.
103 Tapiola T. Biological Markers for Alzheimer´s Disease.
104 Tapiola T et al. CSF tau and Abeta42 levels in patients with Down´s syndrome.
105 Vanhanen M et al. APOE-epsilon4 is associated with weight loss in women with AD . A population-based study.
106 Vartiainen N et al. Piroxicam and NS-398 rescue neurones from hypoxia/reoxygenation damage by a mechanism independent of cyclo-oxygenase inhibition.
107 Waldemar G et al. Benefits of donepezil on cognition, function and neuropsychiatric symptoms in patients with mild and moderate Alzheimr´s disease over one year.
108 Winblad B et al. A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD.
109 Ylinen A et al. Kognitiivisten toimintojen neurobiologinen tausta.
110 Ylinen A, Kanto-Ronkanen A. Seizure-Warning systems and protective adjustments.
111 Äikiä M et al. Verbal memory in newly diagnosed patients and patients with chronic left temporal lobe epilepsy.
112 Åmark P et al. Risk prevention in daily life.

Neurologian yksikkö Department of Neurology
Julkaisutietokanta 15.4.2008 Publications Data Base 15.4.2008